Literature DB >> 8809137

Measurement of anticardiolipin antibodies by ELISA using beta 2-glycoprotein I (beta 2-GPI) in systemic sclerosis.

H Ihn1, S Sato, M Fujimoto, K Kikuchi, A Igarashi, Y Soma, K Tamaki, K Takehara.   

Abstract

In order to determine the prevalence and clinical significance of beta 2-GPI-dependent anticardiolipin antibodies (beta 2-GPI/aCL) in patients with systemic sclerosis (SSc), serum samples from 80 patients with SSc, 20 patients with systemic lupus erythematosus (SLE), and 120 healthy control subjects were examined by ELISA using purified beta 2-GPI. IgG isotype beta 2-GPI/aCL was present in eight of 80 patients with SSc (10%), and the presence of beta 2-GPI/aCL IgG was significantly correlated with the presence of isolated pulmonary hypertension (PH). Furthermore, levels of beta 2-GPI/aCL IgG were significantly correlated with levels of mean pulmonary arterial pressure. These data suggest that IgG isotype beta 2-GPI/aCL might be a serological indicator of the severity of PH in patients with SSc.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8809137      PMCID: PMC2200541          DOI: 10.1046/j.1365-2249.1996.d01-774.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  16 in total

1.  Systemic sclerosis sine scleroderma associated with antiphospholipid syndrome.

Authors:  Pollyanna d'Ávila Leite; Jozélio Freire de Carvalho
Journal:  Rheumatol Int       Date:  2010-04-09       Impact factor: 2.631

2.  Rheumatoid factor isotypes in mixed connective tissue disease.

Authors:  Yoshihiro Mimura; Hironobu Ihn; Masatoshi Jinnin; Yoshihide Asano; Kenichi Yamane; Kunihiko Tamaki
Journal:  Clin Rheumatol       Date:  2006-01-04       Impact factor: 2.980

3.  Clinical features of scleroderma patients with contracture of phalanges.

Authors:  Ryuichi Ashida; Hironobu Ihn; Yoshihiro Mimura; Masatoshi Jinnin; Yoshihide Asano; Masahide Kubo; Kunihiko Tamaki
Journal:  Clin Rheumatol       Date:  2006-12-15       Impact factor: 2.980

4.  Antiphospholipid antibodies in systemic sclerosis: a double oxidative hit?

Authors:  Paul R J Ames
Journal:  Clin Rheumatol       Date:  2009-06-10       Impact factor: 2.980

5.  Serum levels of soluble CD163 in patients with systemic sclerosis.

Authors:  Wakana Nakayama; Masatoshi Jinnin; Katsunari Makino; Ikko Kajihara; Takamitsu Makino; Satoshi Fukushima; Yuji Inoue; Hironobu Ihn
Journal:  Rheumatol Int       Date:  2010-12-01       Impact factor: 2.631

6.  Distribution and antigen specificity of anti-U1RNP antibodies in patients with systemic sclerosis.

Authors:  H Ihn; K Yamane; N Yazawa; M Kubo; M Fujimoto; S Sato; K Kikuchi; K Tamaki
Journal:  Clin Exp Immunol       Date:  1999-08       Impact factor: 4.330

7.  Clinical and laboratory features of scleroderma patients developing skeletal myopathy.

Authors:  Yoshihiro Mimura; Hironobu Ihn; Masatoshi Jinnin; Yoshihide Asano; Kenichi Yamane; Kunihiko Tamaki
Journal:  Clin Rheumatol       Date:  2004-08-20       Impact factor: 2.980

8.  Clinical significance of antiphospholipid antibodies in Indian scleroderma patients.

Authors:  R Gupta; M M Thabah; S Gupta; S Shankar; A Kumar
Journal:  Rheumatol Int       Date:  2009-12       Impact factor: 2.631

9.  Independent association of anti-beta(2)-glycoprotein I antibodies with macrovascular disease and mortality in scleroderma patients.

Authors:  Francesco Boin; Stefano Franchini; Elizabeth Colantuoni; Antony Rosen; Fredrick M Wigley; Livia Casciola-Rosen
Journal:  Arthritis Rheum       Date:  2009-08

Review 10.  Antibodies in scleroderma: direct pathogenicity and phenotypic associations.

Authors:  Lorinda Chung; Paul J Utz
Journal:  Curr Rheumatol Rep       Date:  2004-04       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.